Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00312663 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America
A Phase 1 study of Plasmodium Falciparum Malaria, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00312663: Completed Phase 1 study of Plasmodium Falciparum Malaria, sponsored by U.S. Army Medical Research and Development Command.
NCT00312663 is a Phase 1 study of Plasmodium Falciparum Malaria that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00312663, a Phase 1 study of Plasmodium Falciparum Malaria, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase I/II Trial of a Malaria Vaccine, FMP011/AS01B, in Adults Living in the United States of America.
Primary Outcome
An AE was defined as any reaction, side effect, or untoward event that occurred during the course of the trial whether or not the event was considered related to the study drug or clinically significant. Grade 1: Mild Grade 2: Moderate Grade 3: Severe
Conditions Studied
Interventions
- BIOLOGICAL Falciparum Malaria Protein 11 with AS01B adjuvant.
Study Locations (1)
Maryland
- Walter Reed Army Institute of Research - Silver Spring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2006-04 |
| Est. Completion | 2007-04 |
| Phase | Phase 1 |
What the finished NCT00312663 record still lists
NCT00312663 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Plasmodium Falciparum Malaria appearing as the primary indexed condition, and to 1 intervention - of which Falciparum Malaria Protein 11 with AS01B adjuvant. is the first listed.
NCT00312663 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00312663 about?
NCT00312663 is a clinical study titled "Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America". Phase I/II Trial of a Malaria Vaccine, FMP011/AS01B, in Adults Living in the United States of America.
What is the current status of trial NCT00312663?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2006-04. Estimated completion is 2007-04.
What conditions does trial NCT00312663 study?
This clinical trial studies the following conditions: Plasmodium Falciparum Malaria.
What interventions are being tested in trial NCT00312663?
The interventions under investigation include: Falciparum Malaria Protein 11 with AS01B adjuvant. (BIOLOGICAL).
Who is sponsoring clinical trial NCT00312663?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00312663 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plasmodium Falciparum Malaria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00312663's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia